|Alpha Cognition Inc., of Vancouver, British Columbia||Alpha-602||Progranulin||Amyotrophic lateral sclerosis||FDA granted orphan drug designation|
|Histogen Inc., of San Diego||HST-001||Hair-stimulating complex||Androgenic alopecia||FDA approved its IND, and the company intends to initiate a phase Ib/IIa trial in the second quarter of 2020|
|Moderna Inc., of Cambridge, Mass.||mRNA-1273||mRNA vaccine candidate||COVID-19||FDA granted fast track designation|
|Seattle Genetics Inc., of Bothell, Wash.||Tukysa (tucatinib)||Oral, small-molecule tyrosine kinase inhibitor of HER2||Metastatic HER2-positive breast cancer||Swissmedic granted approval for Tukysa tablets, in combination with trastuzumab and capecitabine, for the treatment of patients who have previously received 2 or more anti-HER2 regimens in any setting|
For more information about individual companies and/or products, see Cortellis.